TherapeuticsMD (NASDAQ:TXMD) Shares Gap Down to $1.20

TherapeuticsMD Inc (NASDAQ:TXMD)’s share price gapped down before the market opened on Monday . The stock had previously closed at $1.13, but opened at $1.20. TherapeuticsMD shares last traded at $1.17, with a volume of 115,208 shares.

TXMD has been the subject of a number of recent research reports. JPMorgan Chase & Co. downgraded shares of TherapeuticsMD from an “overweight” rating to a “neutral” rating in a research note on Tuesday, May 19th. Stifel Nicolaus increased their price objective on shares of TherapeuticsMD from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, April 16th. Zacks Investment Research downgraded shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a research note on Friday, June 5th. BidaskClub downgraded shares of TherapeuticsMD from a “sell” rating to a “strong sell” rating in a research note on Friday, June 19th. Finally, ValuEngine downgraded shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a research note on Tuesday, March 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $8.03.

The company has a debt-to-equity ratio of 22.15, a quick ratio of 3.20 and a current ratio of 3.44. The stock’s fifty day moving average price is $1.22 and its 200-day moving average price is $1.66. The company has a market capitalization of $320.58 million, a P/E ratio of -1.64 and a beta of 2.11.

TherapeuticsMD (NASDAQ:TXMD) last issued its earnings results on Wednesday, May 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.02). The firm had revenue of $12.25 million during the quarter, compared to the consensus estimate of $11.48 million. TherapeuticsMD had a negative net margin of 333.88% and a negative return on equity of 1,170.63%. On average, research analysts predict that TherapeuticsMD Inc will post -0.59 EPS for the current fiscal year.

In related news, CEO Robert G. Finizio purchased 30,000 shares of the stock in a transaction on Friday, June 5th. The shares were purchased at an average cost of $1.15 per share, with a total value of $34,500.00. Following the acquisition, the chief executive officer now directly owns 18,335,964 shares in the company, valued at $21,086,358.60. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 13.76% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. C WorldWide Group Holding A S raised its holdings in TherapeuticsMD by 94.0% in the 1st quarter. C WorldWide Group Holding A S now owns 6,189,834 shares of the company’s stock valued at $6,561,000 after acquiring an additional 3,000,000 shares during the period. State Street Corp raised its holdings in TherapeuticsMD by 17.4% in the 4th quarter. State Street Corp now owns 5,528,827 shares of the company’s stock valued at $13,380,000 after acquiring an additional 820,614 shares during the period. Bamco Inc. NY raised its holdings in TherapeuticsMD by 5.5% in the 4th quarter. Bamco Inc. NY now owns 3,831,500 shares of the company’s stock valued at $9,272,000 after acquiring an additional 200,000 shares during the period. Geode Capital Management LLC raised its holdings in TherapeuticsMD by 10.9% in the 1st quarter. Geode Capital Management LLC now owns 3,343,232 shares of the company’s stock valued at $3,543,000 after acquiring an additional 329,800 shares during the period. Finally, Stifel Financial Corp raised its holdings in TherapeuticsMD by 11.6% in the 4th quarter. Stifel Financial Corp now owns 3,016,412 shares of the company’s stock valued at $7,283,000 after acquiring an additional 313,971 shares during the period. 67.09% of the stock is currently owned by hedge funds and other institutional investors.

About TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD, Inc operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.

Featured Article: What is a Tariff?

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.